| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.1 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.1 |
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | -0.061 | 0.1 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.089 | 0.1 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.1 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.062 | 0.1 |